Director Green purchases 6,000 shares of HUMA at $1.29; concurrent insider buy cluster amid -87.8% decline from 52-week high.
Director Charles Bruce Green purchased 6,000 shares at $1.29 on 2025-04-08, increasing his holdings from 2,400 to 8,400 shares (+250.0% vs pre-transaction holdings). The transaction occurs within a 14-day cluster: 2 other insiders also bought during this same window, suggesting coordinated interest at current levels. The stock trades at $1.15, representing -87.8% from its 52-week high of $9.46 and down -75.4% over 90 days. Humacyte reports negative fundamentals—net income of $-39.2M in its most recent full fiscal year and quarterly revenue of only $241.0K—leaving the strategic rationale for this coordinated buying activity unclear against a backdrop of substantial market repricing.